New Study Reveals Five-Gene Signature for Acute Myeloid Leukemia Prediction

Strategic Insights -

Researchers from the Uniformed Services University of the Health Sciences have made a breakthrough discovery in the field of acute myeloid leukemia (AML) by identifying a five-gene signature that can predict both event-free survival (EFS) and overall survival (OS) in patients with AML. This significant finding has the potential to improve treatment outcomes for patients with AML, a type of cancer that affects both adults and children. The study used gene expression datasets from adult and pediatric AML patients to identify the five-gene signature, which includes F2RL3, IL2RA, MYH15, SIX3, and SOBP. The researchers validated the signature using two independent datasets, demonstrating its robust performance in predicting EFS and OS.

Key Takeaways:

  • A five-gene signature (F2RL3, IL2RA, MYH15, SIX3, and SOBP) was identified to predict event-free survival (EFS) and overall survival (OS) in patients with AML.
  • The signature was validated using two independent datasets, demonstrating its robust performance in predicting EFS and OS.
  • The signature was found to be superior to cytogenetic risk stratification in predicting EFS and OS.
  • The study involved researchers from the Uniformed Services University of the Health Sciences, Penn State Health Children's Hospital, and other institutions.
  • The researchers used gene expression datasets from adult and pediatric AML patients to identify the five-gene signature.
  • The signature was identified using an integrated analysis of adult TCGA and pediatric TARGET expression datasets.
  • The test Area Under the ROC Curves (AUCs) for the 2-year and 5-year cutoffs of adult TCGA data were 0.851 and 0.848, respectively.
  • The test AUCs for the 2-year and 5-year cutoffs of Pediatric TARGET data were 0.725 and 0.695, respectively.
  • The five-gene signature successfully stratified patients into distinct OS groups across two additional independent datasets.

Statistics:

  • The test Area Under the ROC Curves (AUCs) for the 2-year and 5-year cutoffs of adult TCGA data were 0.851 (95% CI: 0.778-0.923) and 0.848 (95% CI: 0.729-0.968), respectively.
  • The test AUCs for the 2-year and 5-year cutoffs of Pediatric TARGET data were 0.725 (95% CI: 0.640-0.811) and 0.695 (95% CI: 0.59-0.80), respectively.
  • The P-values of tertile partitions for TARGET and TCGA data were 2.32e-6 and 5.12e-14, respectively, indicating superior performance compared to cytogenetic risk stratification.

Sources:

  • A Five-Gene Signature for the Prediction of Event-Free Survival of Both Pediatric and Adult Acute Myeloid Leukemia. Diagnostics, 2025, 15(11):1421.
  • Uniformed Services University of the Health Sciences. "New Study Reveals Five-Gene Signature for Acute Myeloid Leukemia Prediction".
  • Penn State Health Children's Hospital Four Diamonds Funds. "Supporting Research to Improve Treatment Outcomes for Pediatric Cancer Patients".